Manuel Ramos

Manuel Ramos

Auto-generated profile, based on publicly available information

Manuel Ramos

Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid, Facultad de Ciencias, 28049 Madrid, Spain

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2003 in Analytical Chemistry
Verified
Journal Article
Closed access
JYJesús Yagüe
Jesús Yagüe
APAlberto Paradela
Alberto Paradela
MRManuel Ramos
Manuel Ramos
SOSamuel Ogueta
Samuel Ogueta
AMAnabel Marina
Anabel Marina
JVJesus Vazquez
Jesus Vazquez

1 September 2002 in Tissue Antigens
Verified
Journal Article
Closed access
PDF file
MRM. Ramos
M. Ramos
JCJ. A. López De Castro
J. A. López De Castro

23 April 2004 in Tissue Antigens
Verified
Journal Article
Closed access
PDF file
LCLopez de Castro
Lopez de Castro
J.J.A.
J.A.
IAIñaki Alvarez
Iñaki Alvarez
MMM. Marcilla
M. Marcilla
APAlberto Paradela
Alberto Paradela
MVM. Vázquez
M. Vázquez

1 October 2002 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MRManuel Ramos
Manuel Ramos
IAIñaki Alvarez
Iñaki Alvarez
LSLaura Sesma
Laura Sesma
ALAntoine Logean
Antoine Logean
DRDidier Rognan
Didier Rognan
JCJosé A. López de Castro
José A. López de Castro
HLA-B27 is strongly associated with spondyloarthropathies, including ankylosing spondylitis and reactive arthritis. The latter disease is triggered by various Gram-negative bacteria. A dodecamer derived from the intracytoplasmic tail of HLA-B27 was a natural ligand of three disease-associated subtypes (B*2702, B*2704, and B*2705) but not of two (B*2706 and B*2709), weakly or not associated to spondyloarthropathy. This peptide was strikingly homologous to protein sequences from arthritogenic bacteria, particularly to a region of the DNA primase from Chlamydia trachomatis. A synthetic peptide with this bacterial sequence bound in vitro disease-associated subtypes equally as the natural B27-derived ligand. The chlamydial peptide was generated by the 20 S proteasome from a synthetic 28-mer with the sequence of the corresponding region of the bacterial DNA primase. Molecular modeling suggested that the B27-derived and chlamydial peptides adopt very similar conformations in complex with B*2705. The results demonstrate that an HLA-B27-derived peptide mimicking arthritogenic bacterial sequences is a natural ligand of disease-associated HLA-B27 subtypes and suggest that the homologous chlamydial peptide might be presented by HLA-B27 on Chlamydia-infected cells.

1 August 2002 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MRManuel Ramos
Manuel Ramos
APAlberto Paradela
Alberto Paradela
MVMiriam Vázquez
Miriam Vázquez
AMAnabel Marina
Anabel Marina
JVJesus Vazquez
Jesus Vazquez
JCJosé A. López de Castro
José A. López de Castro
In contrast to HLA-B*2705, B*2709 is weakly or not associated to ankylosing spondylitis. Both allotypes differ by a single D116H change. We compared the B*2705- and B*2709-bound peptide repertoires by mass spectrometry to quantify the effect of B*2709 polymorphism on peptide specificity. In addition, shared and differentially bound ligands were sequenced to define the structural features of the various peptide subsets. B*2705 shared 79% of its peptide repertoire with B*2709. Shared ligands accounted for 88% of the B*2709-bound repertoire. All B*2705 ligands not bound to B*2709 had C-terminal basic or Tyr residues. Most B*2709-bound peptides had C-terminal aliphatic and Phe residues, but two showed C-terminal Arg or Tyr. The B*2709-bound repertoire included 12% of peptides not found in B*2705. These had aliphatic C-terminal residues, which are also favored in B*2705. However, these peptides bound weakly B*2705 in vitro, indicating distinct contribution of secondary anchor residues in both subtypes. Differences in peptide binding did not affect the ratio of native to β2-microglobulin-free HLA-B27 heavy chain at the cell surface. Our results suggest that weaker association of B*2709 with ankylosing spondylitis is based on differential binding of a limited subset of natural ligands by this allotype.

1 October 2009 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
FMFrancisco Medina
Francisco Medina
MRManuel Ramos
Manuel Ramos
Salvador IborraSalvador Iborra
Salvador Iborra
PLPatricia de León
Patricia de León
MRMarta Rodríguez-Castro
Marta Rodríguez-Castro
MVMargarita Del Val
Margarita Del Val
Most pathogen-derived peptides recognized by CD8+ CTL are produced by proteasomes and delivered to the endoplasmic reticulum by the TAP transporters associated with Ag processing. Alternative proteases also produce antigenic peptides, but their actual relevance is unclear. There is a need to quantify the contribution of these supplementary pathways in vitro and in vivo. A well-defined TAP-independent secretory route of Ag processing involves the trans-Golgi network protease furin. Quantitation of this route by using OVA constructs encoded by vaccinia viruses indicates that it provides approximately one-third of all surface complexes of peptide and MHC class I molecules. Generation of the epitope carboxyl terminus is a dramatic rate-limiting step, since bypassing it increased efficiency by at least 1000-fold. Notably, the secretory construct activated a similar percentage of Ag-specific CD8+ T cells in wild type as in TAP1-deficient mice, which allow only secretory routes but which have a 10- to 20-fold smaller CD8 compartment. Moreover, these TAP1−/− OVA-specific CD8+ T lymphocytes accomplished elimination of epitope-bearing cells in vivo. The results obtained with this experimental system underscore the potential of secretory pathways of MHC class I Ag presentation to elicit functional CD8+ T lymphocytes in vivo and support the hypothesis that noncytosolic processing mechanisms may compensate in vivo for the lack of proteasome participation in Ag processing in persons genetically deficient in TAP and thus contribute to pathogen control.